ENTITY
Lupin Ltd

Lupin Ltd (LPC IN)

142
Analysis
Health CareIndia
Lupin Limited manufactures bulk actives and formulations. The principal bulk actives manufactured by it include Rifampicin, Pyrazinamide, Ethambutol (anti-TB), Cephalosporins (anti-infectives) and cardiovasculars. The company also possesses competencies in phytomedicines, in which medicines are made out of plant and herbal resources supported by the discipline of modern medicine.
more
Refresh
21 Jul 2022 10:20

NIFTY100 Index Rebalance Preview: Couple of Changes in August, Then 5 More in September

There are two index changes at the close on 5 August, then there should be 5 more at the close on 29 September. Passive funds will have over 4-5...

Logo
523 Views
Share
12 Jul 2022 10:08

NIFTY100 & CPSE Index Rebalance: Some Big Changes in 3 Weeks

LIC and Tata Power will be added to the NIFTY100 Index at the close on 5 August. NMDC is being deleted from the NIFTY100 & CPSE indices. There is a...

Logo
561 Views
Share
bullishLupin Ltd
23 May 2022 08:41Broker

Lupin - Disappointing Quarter; Focus on Driving Cost Efficiencies

We maintain our Buy rating on Lupin, but lower our estimates to account for lower US sales and cost pressures. EBITDA margin came in at 7% for the...

Logo
204 Views
Share
22 May 2022 17:54

Dr. Reddy's Laboratories (DRRD IN) 4QFY22: Double-Digit Sales Growth; One-Off Charge Impacted Profit

Dr. Reddy’s reported strong double-digit revenue growth in Q4, while one-off charges weighed on bottom-line. New product launches in the U.S....

Logo
275 Views
Share
16 May 2022 10:15

NIFTY100 Index Rebalance Preview: Five Potential Changes in September

We see five potential changes to the NIFTY100 Index at the September rebalance. Most are high probability changes and there will be over 1.5 days...

Logo
433 Views
Share
x